Search

Your search keyword '"Chengwan Xia"' showing total 2 results
Start Over Author "Chengwan Xia" Journal journal of materials chemistry. b
2 results on '"Chengwan Xia"'

1. A thermally activated delayed fluorescence photosensitizer for photodynamic therapy of oral squamous cell carcinoma under low laser intensity

Author

Xiaofeng Huang, Sulong Guo, Bin Huang, Qian Zhang, Yumei Pu, Chengwan Xia, Shiqi Hu, and Yuxin Wang

Subjects
Cell Survival, medicine.medical_treatment, Biomedical Engineering, Mice, Nude, Photodynamic therapy, Anthraquinones, Antineoplastic Agents, Biocompatible Materials, Fluorescence, Mice, In vivo, medicine, Tumor Cells, Cultured, Animals, Humans, General Materials Science, Basal cell, Photosensitizer, Irradiation, Particle Size, Cell Proliferation, Photosensitizing Agents, Dose-Response Relationship, Drug, Molecular Structure, Singlet Oxygen, Chemistry, Squamous Cell Carcinoma of Head and Neck, Temperature, Cancer, General Chemistry, General Medicine, Neoplasms, Experimental, medicine.disease, Photochemotherapy, Cancer cell, Cancer research, Mouth Neoplasms, Drug Screening Assays, Antitumor
Abstract

In this report, a new thermally activated delayed fluorescence (TADF) molecule [2-(4-triphenylvinyl-phenyl)-anthraquinone (TPE-AQ)] was synthesized. This nanomaterial has satisfactory photostability. Through In vitro analysis, it was found that these TADF nanoparticles (NPs) targeted lysosomes in oral cancer cells. ROS were released under irradiation with a 450-nm laser, and the growth of xenograft tumors in mouse models was inhibited in vivo. More interestingly, radiation exposure caused little damage to normal tissues due to the low irradiation intensity (mA) used in the photodynamic therapy (PDT) treatment of oral cancer. Therefore, these TADF NPs provide new possibilities for the development of new PDT drugs for biomedical applications. In future work, possible functional modifications of TADF NPs for increased potency in clinical applications will be addressed.

Published
2021

2. Glutathione-sensitive and folate-targeted nanoparticles loaded with paclitaxel to enhance oral squamous cell carcinoma therapy

Author

Yuxin Wang, Chengwan Xia, Jianquan Wang, Yumei Pu, Qian Zhang, Liang Chen, Lei Fan, and Jianfang Chen

Subjects
Drug, Male, Paclitaxel, Surface Properties, media_common.quotation_subject, Biomedical Engineering, Endocytosis, chemistry.chemical_compound, Mice, Folic Acid, In vivo, Tumor Cells, Cultured, Animals, Humans, General Materials Science, Particle Size, Receptor, media_common, Cell Proliferation, Mice, Inbred BALB C, Chemistry, technology, industry, and agriculture, General Chemistry, General Medicine, Glutathione, Neoplasms, Experimental, Antineoplastic Agents, Phytogenic, In vitro, Drug Liberation, Drug delivery, Cancer research, Carcinoma, Squamous Cell, Nanoparticles, Mouth Neoplasms, Drug Screening Assays, Antitumor
Abstract

In this study, a drug delivery system based on glutathione (GSH)-sensitive and folic acid (FA)-targeted nanoparticles loaded with paclitaxel (FA-PEG-S-S-PCL@PTX, FA-NPs) was developed. First, we proved that the FA receptor was significantly expressed in 95 oral squamous cell carcinoma (OSCC) specimens (57.9%). This provided feasibility to release FA-targeted nanoparticles in tumour sites for patients with OSCC. Next, FA-NPs were synthesized and characterized. In vitro, we found enhancement in FA-mediated endocytosis in the HSC3 cells with FA overexpression. Therefore, paclitaxel (PTX) from FA-NPs could be precisely released due to the disulfide bonds that were cleaved by a redox reaction. In vivo, FA-NPs could be accumulated in mice bearing HSC3 cells, where they exhibited effective antitumor effects when compared to the treatments with free PTX and PEG-S-S-PCL@PTX. In summary, this novel drug system has an opportunity to improve OSCC treatment.

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results